Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease.

Autor:	Billiet T; a Department of Clinical and Experimental Medicine, Translational Research Center for GastroIntestinal Disorders (TARGID) , KU Leuven , Leuven , Belgium., Cleynen I; a Department of Clinical and Experimental Medicine, Translational Research Center for GastroIntestinal Disorders (TARGID) , KU Leuven , Leuven , Belgium., Ballet V; b Department of Gastroenterology and Hepatology , University Hospitals Leuven, KU Leuven , Leuven , Belgium., Claes K; a Department of Clinical and Experimental Medicine, Translational Research Center for GastroIntestinal Disorders (TARGID) , KU Leuven , Leuven , Belgium., Princen F; c Department of Research and Development , Prometheus Laboratories , San Diego , CA , USA., Singh S; c Department of Research and Development , Prometheus Laboratories , San Diego , CA , USA., Ferrante M; a Department of Clinical and Experimental Medicine, Translational Research Center for GastroIntestinal Disorders (TARGID) , KU Leuven , Leuven , Belgium.; b Department of Gastroenterology and Hepatology , University Hospitals Leuven, KU Leuven , Leuven , Belgium., Van Assche G; a Department of Clinical and Experimental Medicine, Translational Research Center for GastroIntestinal Disorders (TARGID) , KU Leuven , Leuven , Belgium.; b Department of Gastroenterology and Hepatology , University Hospitals Leuven, KU Leuven , Leuven , Belgium., Gils A; d Department of Pharmaceutical and Pharmacological Sciences, Laboratory for Therapeutic and Diagnostic Antibodies , KU Leuven , Leuven , Belgium., Vermeire S; a Department of Clinical and Experimental Medicine, Translational Research Center for GastroIntestinal Disorders (TARGID) , KU Leuven , Leuven , Belgium.; b Department of Gastroenterology and Hepatology , University Hospitals Leuven, KU Leuven , Leuven , Belgium.
Jazyk:	angličtina
Zdroj:	Scandinavian journal of gastroenterology [Scand J Gastroenterol] 2017 Oct; Vol. 52 (10), pp. 1086-1092. Date of Electronic Publication: 2017 Jun 16.
DOI:	10.1080/00365521.2017.1339825
Abstrakt:	Objective: Primary non-response to infliximab in Crohn's disease is still incompletely understood. Our aim was to further characterize the role of inflammatory burden during infliximab induction therapy. Materials and Methods: We studied a well-characterized cohort of 201 anti-TNF naive Crohn's disease patients treated with infliximab 5mg/kg at week 0, 2, 6 and 14 who had serum samples drawn just before every infusion. All serum samples were analyzed for CRP, albumin, TNF, IFN-γ, IL-6, IL-8, IL-10, infliximab trough concentrations (in-house-developed ELISA) and antibodies to infliximab (HMSA, Prometheus Laboratories Inc., San Diego, CA). Primary non-response was defined as the absence of clinical improvement at week 14. Results: The incidence of primary non-response to infliximab was 8% (n = 16). IL-8 concentrations at baseline were higher (p = .01) and albumin at week 6 was lower in primary non-responders (p = .01) compared to responders. During induction, IFN-γ and IL-6 concentrations decreased significantly at week 2 and week 6 in responders compared to primary non-responders (p < .05). Serum TNF increased significantly after each infliximab infusion and this increase from week 0 to week 14 was more pronounced in responders (p = .03). Multiple logistic regression identified TNF/CRP ratio at baseline as predictive for primary non-response to infliximab at week 14 (OR 2.8 (95% CI 1.4-5.5; p = .003)). Conclusions: In this intensively sampled cohort of Crohn's disease patients, we demonstrate that inflammatory burden is more determining for primary non-response than drug exposure or immunogenicity. Our findings furthermore suggest that the contribution of TNF in inflammation might be higher in primary non-response, contradicting the non-TNF-driven concept.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu